Repligen Corporation (NASDAQ: RGEN)

Repligen Corporation (NASDAQ: RGEN) has focused their efforts on the development of innovative therapeutics for neurological disorders. The company’s current clinical development programs are being conducted in the areas of pancreatic MRI imaging, bipolar disorder, Friedreich’s ataxia and Huntington’s disease. Repligen generates profits from its recombinant Protein A and has a secured source of revenue via its licensing of CTLA4-Ig. The company also receives royalties from Bristol-Myers Squibb. For further information, visit the Company’s web site at www.repligen.com.